finish top-lin guid
ahead margin still pressur
upsid driven sale growth ahead
total sale grew y/i vs our/street est
upsid due gain acquisit vs estimate
better organ growth vs estimate tabl lcd rev
our/street est visibl alpha driven
organ lab volum grew vs estimate street revenu
per requisit saw organ growth vs estimate cdd revenu
vs our/street visibl alpha organ growth
ahead estimate book-to-bil ttm basi vs estimate
ep ahead our/street est detail pg
sale guid better expect ep in-lin
lh initi guid see total revenu growth
midpoint vs street segment lcd revenu expect
grow cdd management indic lcd normal organ growth
exclud headwind pama beacon non-renew partial off-set
extra day fx cdd organ growth like msd-hsd rang total
compani oper margin flat slightli y/i margin gain cdd
off-set lcd declin ep rang midpoint
vs street capit deploy upsid driver expect
tweak est reiter neutral rais po
overal lh end high note encourag better
expect top-lin guid lcd stabil cdd core growth improv
forecast sale vs prior howev
lower est due conserv
margin interest expens share buy-back expect rais po
po still base sotp analysi use multipl lcd
multipl cdd ev/ebitda estimate reiter neutral rate
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
pama protect access
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lh second-largest clinic laboratori
 intern invest acquisit
compani expand clinic diagnost
technolog offer better insul
growth rate lh also expand contract
research organ industri
acquisit covanc chiltern account
market share global
although see upsid potenti elev
lab consolid catalyz medicar
opportun monet lab data recent
multipl guidanc cut suggest visibl
limit said posit lh
abil weather headwind strong
industri trend drive higher growth
compani cro contract research
lcd margin weaken cro op continu improv
lh gross profit grew gross margin slightli
cdd margin improv larg off-set lcd margin weak lcd
ebita ebita margin declin y/i primarili
due pama price cut labor cost cyber invest cdd busi saw ebita
growth ebita margin y/i
tabl overview lh perform
po base sotp analysi assum multipl lh lcd lab
segment in-lin clinic lab histor three-year median forward multipl
multipl cdd cro segment in-lin peer ev/ebitda
upsid risk faster expect materi hospit lab consolid
trend smaller expect share loss contract retail clinic opportun
monet data lab cro busi significantli faster
cro growth margin improv
downsid risk greater expect price headwind lower expect test
volum growth competit execut risk integr risk data privaci risk
regulatori risk covanc drug develop side lh like get much
credit cdd well expect given peer get punish
downsid sentiment wane segment fall short
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
